BGB-16673: A Comprehensive Clinical and Strategic Analysis of a First-in-Class BTK Protein Degrader

I. Synopsis and Therapeutic Rationale

Introduction to BGB-16673

BGB-16673 is an investigational, orally available, first-in-class therapeutic agent engineered to address key challenges in the treatment of B-cell malignancies. Developed by BeiGene, BGB-16673 is the lead asset from the company's proprietary Chimeric Degradation Activation Compound (CDAC) platform.[1] It is classified as a Bruton's Tyrosine Kinase (BTK) targeted protein degrader, a novel class of molecules also known as Proteolysis-Targeting Chimeras (PROTACs). Unlike traditional kinase inhibitors that aim to block the enzymatic function of a target protein, BGB-16673 is designed to induce the complete elimination of the BTK protein from the cancer cell, representing a fundamental shift in therapeutic strategy.[3] This distinct mechanism of action provides a strong rationale for its development as a potential treatment for patients who have developed resistance or intolerance to existing BTK-targeting therapies.[6]

The Unmet Need in B-Cell Malignancies

Bruton's Tyrosine Kinase is a non-receptor tyrosine kinase that serves as an indispensable component of the B-cell receptor (BCR) signaling pathway.[4] This pathway is a critical regulator of B-cell proliferation, differentiation, and survival. In numerous B-cell malignancies—including Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenström Macroglobulinemia (WM), Mantle Cell Lymphoma (MCL), and Marginal Zone Lymphoma (MZL)—the BCR pathway is constitutively active, driving oncogenesis and making BTK a validated and highly valuable therapeutic target.[4]

The introduction of covalent BTK inhibitors (cBTKis), such as ibrutinib, acalabrutinib, and zanubrutinib, revolutionized the management of these diseases, offering durable responses and improved survival compared to conventional chemoimmunotherapy.[8] These agents form an irreversible bond with a cysteine residue at position 481 (C481) in the BTK active site. However, their long-term efficacy is frequently compromised by the emergence of on-target resistance, most commonly through mutations at the C481 binding site (e.g., C481S), which prevent covalent binding and restore kinase activity.[8]

The development of non-covalent, reversible BTK inhibitors (ncBTKis), such as pirtobrutinib (Jaypirca), provided a significant advancement, as these agents can effectively inhibit BTK even in the presence of C481 mutations.[8] Despite this, resistance to ncBTKis also emerges through a different set of on-target mutations within the kinase domain (e.g., V416L, T474I, L528W) that reduce drug affinity.[8] Furthermore, a subset of patients must discontinue BTK inhibitor therapy due to intolerance and off-target adverse events.[10] Consequently, there remains a substantial and growing unmet medical need for novel therapies that can effectively target BTK in patients who have progressed on or are intolerant to both covalent and non-covalent inhibitors, a population with limited therapeutic options and poor prognosis.[3]

The core therapeutic premise of BGB-16673 is founded on a fundamentally different pharmacological approach. Traditional inhibitors, both covalent and non-covalent, rely on sustained occupancy of the BTK active site to block its function. This "occupancy-driven" model is inherently vulnerable to mutations that alter the binding pocket, allowing the kinase to escape inhibition. BGB-16673, in contrast, operates via an "event-driven" mechanism. It acts catalytically, tagging the entire BTK protein for destruction by the cell's own machinery.[4] By removing the protein entirely, this approach is designed to be agnostic to mutations within the kinase binding site. This mechanism not only eliminates the enzymatic activity of BTK but also abrogates any potential non-enzymatic scaffolding functions the protein might have, leading to a more profound and potentially more durable suppression of the BCR pathway.[1] This mechanistic distinction forms the scientific basis for the hypothesis that BGB-16673 can overcome the primary modes of resistance to all existing classes of BTK inhibitors, a hypothesis that is now being rigorously evaluated in a comprehensive clinical development program.[10]

II. Molecular Profile and Mechanism of Action

Classification and Structure

BGB-16673 is a heterobifunctional small molecule, a structural characteristic of the PROTAC drug class, which BeiGene refers to as a Chimeric Degradation Activation Compound (CDAC).[1] Its design incorporates two distinct active domains connected by a chemical linker. One domain, or "warhead," is engineered to bind with high affinity to the target protein, BTK. The other domain is designed to recruit a component of the cellular protein degradation machinery, specifically the E3 ubiquitin ligase cereblon (CRBN).[10] This bivalent architecture is the key to its unique mechanism of action, enabling it to function as a molecular bridge between the target protein and the degradation system.

The Degradation Cascade

The mechanism of action of BGB-16673 is a multi-step process that hijacks the cell's natural ubiquitin-proteasome system (UPS) to achieve targeted protein degradation. The UPS is the primary pathway for regulated protein turnover in eukaryotic cells, and BGB-16673 effectively redirects this system to recognize BTK as a substrate for elimination. The cascade proceeds as follows:

1. Ternary Complex Formation: BGB-16673 simultaneously binds to BTK and the E3 ligase CRBN, forming a transient but productive ternary complex (BTK−BGB16673−CRBN).[10] The formation of this complex brings the BTK protein into close physical proximity with the enzymatic machinery of the E3 ligase.
2. Ubiquitination: Within the ternary complex, the E3 ligase catalyzes the covalent attachment of multiple ubiquitin molecules, a small regulatory protein, onto lysine residues on the surface of the BTK protein.[10] This process, known as poly-ubiquitination, serves as a molecular "tag" or signal for degradation.
3. Proteasomal Degradation: The poly-ubiquitinated BTK protein is then recognized by the 26S proteasome, a large protein complex that functions as the cell's primary non-lysosomal protease.[4] The proteasome unfolds and degrades the tagged BTK protein into small peptides, effectively eliminating it from the cell.
4. Catalytic Cycle: After inducing ubiquitination, BGB-16673 dissociates from the complex and is free to bind to another BTK molecule, initiating a new cycle of degradation. This catalytic nature means that a single molecule of BGB-16673 can induce the destruction of multiple BTK protein molecules, potentially leading to profound and sustained target suppression even at low drug concentrations.[13]

This process results in a rapid, deep, and durable reduction in the total cellular concentration of BTK protein, as has been demonstrated in both peripheral blood and tumor tissue from patients in clinical trials.[12] By eliminating the protein, BGB-16673 effectively shuts down BCR signaling and its downstream pathways, ultimately leading to the inhibition of tumor cell growth and the induction of apoptosis.[4]

Preclinical Validation and Superiority

An extensive body of preclinical research provides a robust foundation for the clinical development of BGB-16673. These studies have not only validated its mechanism of action but have also suggested key points of differentiation and potential superiority over existing BTK inhibitors.

• Activity Against Resistant Mutants: In cellular assays, BGB-16673 demonstrated potent degradation of both wild-type BTK and a comprehensive panel of clinically relevant mutant forms known to confer resistance to both cBTKis (e.g., C481S, C481F, C481Y, T474I, L528W) and ncBTKis (e.g., V416L, M437R, T474I, L528W).[8] This broad activity is a direct consequence of its degradation mechanism, which is not dependent on binding to a specific conformation of the kinase active site that may be altered by mutation.
• Superior Anti-Proliferative Effects: In lymphoma cell lines and xenograft models harboring these resistance mutations, BGB-16673 exhibited superior anti-proliferative activity and induced more profound inhibition of downstream signaling (e.g., phosphorylation of PLCγ2) compared to both the cBTKi ibrutinib and the ncBTKi pirtobrutinib (referred to as LOXO-305 in preclinical studies).[8] In animal models, BGB-16673 was capable of driving complete and durable tumor regressions in tumors expressing these mutations and was more effective at controlling bulky disease.[8]
• Reduced Propensity to Induce New Resistance: Perhaps one of the most compelling preclinical findings relates to the generation of new resistance. In a cellular mutagenesis screen designed to induce resistance, treatment with BGB-16673 resulted in the emergence of on-target BTK mutations in only 12.7% of resistant clones. In stark contrast, treatment with pirtobrutinib or a non-degrading BTK-binding molecule resulted in BTK mutations in 100% of resistant clones.[9]

These preclinical findings suggest a significant dual advantage for BGB-16673. First, its ability to degrade a wide spectrum of known mutants provides a clear strategy to overcome existing resistance in patients who have failed prior BTK inhibitors. Second, and more profound from a long-term strategic perspective, its lower propensity to generate new on-target resistance suggests that the degradation mechanism is inherently more robust and difficult for cancer cells to evade through simple point mutations in the BTK gene. To escape degradation, a cancer cell would likely need to develop more complex mechanisms, such as altering the E3 ligase or the proteasome system, which may be less likely to occur. This compelling preclinical profile provides a strong scientific rationale for the aggressive clinical development strategy pursued by BeiGene, which includes not only evaluating BGB-16673 in a late-line setting but also positioning it to directly challenge the leading ncBTKi in a head-to-head clinical trial.[21]

Attribute	Description	Supporting Sources
Drug Name	BGB-16673	10
Developer	BeiGene	2
Drug Class	BTK Targeted Protein Degrader; Chimeric Degradation Activating Compound (CDAC); Proteolysis-Targeting Chimera (PROTAC)	1
Mechanism of Action	Heterobifunctional molecule that forms a ternary complex with BTK and the E3 ligase cereblon (CRBN), inducing poly-ubiquitination and subsequent proteasomal degradation of the BTK protein.	4
Key Preclinical Differentiators	Potent degradation of wild-type BTK and mutant forms conferring resistance to both covalent (e.g., C481S) and non-covalent (e.g., V416L, T474I) BTK inhibitors. Lower propensity to induce new on-target resistance mutations compared to kinase inhibitors.	8

III. The CaDAnCe Clinical Development Program

The clinical development of BGB-16673 is being executed through a comprehensive and notably ambitious program named CaDAnCe. This program is designed to rapidly evaluate the drug's safety and efficacy across a spectrum of B-cell malignancies and to strategically position it within the evolving treatment landscape. The program's structure reflects a high degree of confidence in the molecule's preclinical profile, progressing swiftly from a first-in-human study to multiple pivotal Phase 3 trials, including a direct head-to-head comparison with a key competitor.[21]

CaDAnCe-101 (NCT05006716): The Foundational Study

The cornerstone of the clinical program is the CaDAnCe-101 trial, an ongoing, global, open-label, first-in-human, Phase 1/2 study.[10]

• Study Design and Objectives: The trial is structured in two main parts. Part 1 is a dose-finding phase, which includes both dose-escalation and dose-expansion cohorts, utilizing a Bayesian optimal interval design to assess multiple dose levels (ranging from 50 mg to 600 mg once daily).[10] The primary objectives of this phase are to evaluate the safety and tolerability of BGB-16673, determine the Maximum Tolerated Dose (MTD), and establish the Recommended Phase 2 Dose (RP2D).[2] Part 2 consists of expansion cohorts at the RP2D in specific disease types to further characterize efficacy and safety.[20] Secondary objectives across the study include characterization of pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity.[2]
• Patient Population: CaDAnCe-101 enrolls a broad population of adult patients with relapsed or refractory (R/R) B-cell malignancies who have exhausted standard therapeutic options. Eligible histologies include Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Waldenström Macroglobulinemia (WM), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), Diffuse Large B-cell Lymphoma (DLBCL), and Richter Transformation (RT).[12] A critical inclusion criterion for many of the cohorts, particularly in the US, EU, and Australia, is that patients must have received at least two prior lines of therapy and have been previously treated with a covalent BTK inhibitor (cBTKi) if one is approved for their disease.[10]

Pivotal Phase 3 Trials

Building on the promising data from CaDAnCe-101, BeiGene has initiated a series of pivotal Phase 3 trials designed to secure regulatory approval and establish BGB-16673 as a new standard of care in key patient populations.

• CaDAnCe-302 (NCT06846671): This is a randomized, open-label Phase 3 study evaluating BGB-16673 versus investigator's choice of therapy in patients with R/R CLL/SLL who have been previously treated with both a BTK inhibitor and a BCL2 inhibitor.[21] This "double-refractory" population represents a significant unmet need. The comparator arm includes regimens such as idelalisib plus rituximab, bendamustine plus rituximab, or retreatment with venetoclax plus rituximab.[31] The primary endpoint is progression-free survival (PFS). This trial targets a late-line setting where BGB-16673 could potentially gain its first approval.
• NCT06973187 (Head-to-Head vs. Pirtobrutinib): In a bold strategic move, BeiGene has launched a Phase 3, open-label, randomized trial directly comparing BGB-16673 against the non-covalent BTK inhibitor pirtobrutinib (Jaypirca).[21] The study enrolls patients with R/R CLL/SLL who have previously been treated with a cBTKi. This trial is designed to test the hypothesis that BTK degradation is a superior therapeutic strategy to non-covalent inhibition in the second-line setting for BTKi-pretreated patients. Its outcome will be a defining event for the BTK degrader class and could reshape the treatment paradigm after cBTKi failure.
• CaDAnCe-303 (NCT06970743): This Phase 3 study compares BGB-16673 with investigator's choice of therapy in patients with CLL/SLL who have previously received a covalent BTK inhibitor, providing another pathway to registration in this key patient population.[32]

Combination Studies (NCT06634589)

Recognizing that the future of cancer therapy often lies in combination regimens, BeiGene has initiated a Phase 1b/2 master protocol study (NCT06634589) to explore the potential of BGB-16673 when combined with other targeted and immunotherapeutic agents.[33] This study is designed with multiple substudies to evaluate BGB-16673 in combination with:

• Sonrotoclax (BGB-11417): A next-generation BCL2 inhibitor.
• Zanubrutinib (Brukinsa): A covalent BTK inhibitor.
• Mosunetuzumab and Glofitamab: CD20xCD3 T-cell engaging bispecific antibodies.
• Obinutuzumab: An anti-CD20 monoclonal antibody. This master protocol allows for the efficient evaluation of multiple rational combinations aimed at achieving deeper and more durable responses by targeting complementary resistance pathways.

Regulatory Status

The promising early clinical data and the significant unmet need that BGB-16673 aims to address have been recognized by global regulatory authorities, leading to expedited development pathways.

• FDA Fast Track Designation: The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BGB-16673 for the treatment of adult patients with R/R CLL/SLL who have received two or more prior lines of therapy, as well as for R/R MCL.[2]
• EMA PRIME Designation: The European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation for the treatment of patients with WM who have previously received a BTK inhibitor.[40]

These designations facilitate more frequent interactions with regulatory agencies and can lead to eligibility for accelerated approval and priority review, potentially shortening the time to market. The decision to launch a head-to-head trial against the established next-in-class competitor, pirtobrutinib, rather than solely pursuing approval in a later-line salvage setting, is a clear indicator of a high-risk, high-reward strategy. This approach is not typical for a first-in-class agent and is likely predicated on the strength of the preclinical data suggesting superiority in overcoming and preventing resistance, combined with the strong early clinical signals of high efficacy in patients who have already failed ncBTKis.[3] This strategy demonstrates that BeiGene is not merely aiming for BGB-16673 to become another therapeutic option but is actively positioning it to potentially displace ncBTKis as the preferred standard of care following cBTKi failure.

IV. Clinical Efficacy in Relapsed/Refractory B-Cell Malignancies

Data from the ongoing CaDAnCe-101 study have demonstrated promising and clinically meaningful anti-tumor activity for BGB-16673 across a range of heavily pretreated B-cell malignancies. The results have been particularly robust in CLL/SLL and WM, with encouraging signals in indolent non-Hodgkin lymphomas as well.

A. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

The CLL/SLL cohort in the CaDAnCe-101 study represents a patient population with advanced disease and a high degree of treatment resistance, providing a rigorous test for a novel agent.

• Patient Cohort Profile: Patients enrolled in this cohort were heavily pretreated, with a median of 4 prior lines of therapy.[5] The population was enriched for high-risk features and resistance to standard-of-care agents. Data from various presentations show that 92-94% of patients had received a prior cBTKi, 82-86% a prior BCL2 inhibitor (e.g., venetoclax), and 21-24% had even received a prior ncBTKi.[10] Genomically, the cohort was characterized by a high prevalence of poor-prognosis markers, including del(17p) and/or TP53 mutations (47-63%) and unmutated IGHV status (78-82%).[5] The vast majority of patients (89%) had discontinued their prior BTK inhibitor due to disease progression rather than toxicity.[43]
• Efficacy Data: Across multiple data cuts presented at major hematology congresses, BGB-16673 has shown consistent and high rates of response that appear to deepen with longer follow-up.
• Overall Response Rate (ORR): The ORR, defined as a partial response with lymphocytosis (PR-L) or better, has been consistently high. Initial reports cited rates of 72% and 78%.[2] More mature data presented at the EHA 2025 Congress, with a median follow-up of 15.6 months in 66 evaluable patients, reported an ORR of 84.8%.[43] An earlier abstract for the same meeting cited an ORR of 80.3%.[11]
• Dose-Response and Recommended Phase 2 Dose (RP2D): A clear dose-response relationship was observed during dose escalation. The 200 mg once-daily dose level consistently demonstrated the highest efficacy, with an ORR of 88% to 94% reported in this subgroup.[2] Based on its favorable efficacy and safety profile, 200 mg once daily was selected as the RP2D for further study.
• Depth and Durability of Response: While the primary responses are partial responses, complete responses (CR) or CR with incomplete marrow recovery (CRi) are beginning to emerge with longer treatment duration, with rates reported between 3.0% and 4.5%.[10] The responses have proven to be durable. At a median follow-up of approximately 15 months, the median progression-free survival (PFS) had not yet been reached, and the estimated 12-month PFS rate was 77.4% ( 95% CI, 63.1%−86.8%).[11]
• Time to Response: The onset of response is rapid, with a median time to first response of approximately 2.8 months.[2]
• Efficacy in High-Risk Subgroups: A critical finding is the consistent efficacy of BGB-16673 across the most difficult-to-treat patient subgroups. High ORRs were maintained in patients with prior exposure to both a cBTKi and a BCL2 inhibitor ("double-exposed," ORR 90.5%) and even in those exposed to a cBTKi, a BCL2 inhibitor, and an ncBTKi ("triple-exposed," ORR 75.0%).[10] Furthermore, the drug was active in patients with and without BTK mutations (ORR 70.8% and 84.6%, respectively) and in those with high-risk genomic features like del(17p) and/or TP53 mutations (ORR 81.4%).[10]

Efficacy Endpoint	Overall Population (N=66)	200 mg Dose (N=16)	Double-Exposed (cBTKi + BCL2i)	Triple-Exposed (cBTKi + BCL2i + ncBTKi)	BTK-Mutant
ORR (PR-L or better)	80.3% - 84.8%	93.8%	87.8% - 90.5%	75.0%	70.8% - 75.0%
CR/CRi Rate	3.0% - 4.5%	6.3% (1 CR)	N/A	N/A	N/A
Median Time to First Response	2.8 months	N/A	N/A	N/A	N/A
12-Month PFS Rate	77.4%	N/A	N/A	N/A	N/A
Data compiled from multiple presentations of the CaDAnCe-101 study, primarily EHA 2025 reports.11 N values for subgroups vary between reports.

B. Waldenström Macroglobulinemia (WM)

BGB-16673 has demonstrated particularly striking activity in patients with R/R WM, leading to the EMA granting it PRIME designation for this indication.[40]

• Patient Cohort Profile: The WM cohort was also heavily pretreated, with a median of 3.5 prior therapies.[46] Critically, 100% of patients had received a prior cBTKi, 91% had received prior chemotherapy, and 14% had received a prior ncBTKi.[46] The population had a high prevalence of key prognostic mutations, including MYD88 (89-91%), CXCR4 (36-54%), and TP53 (52%).[40]
• Efficacy Data: The efficacy results in WM are among the most impressive for BGB-16673 to date.
• Overall Response Rate (ORR): The ORR (minor response or better) was exceptionally high, reported at 84.4% to 90% across 21-32 response-evaluable patients.[18]
• Major Response Rate (MRR): The rate of deep responses was also substantial, with an MRR (partial response or better) of 75% to 81%.[40] The Very Good Partial Response (VGPR) rate was reported to be between 14% and 31.3%, indicating that a significant fraction of patients achieve deep remissions.[18]
• Time to Response: Responses were notably rapid, with a median time to first response of just 0.95 to 1.0 month.[40] Responses were observed to deepen over time, and the majority of responding patients remained on treatment at the time of data cutoff.[46]
• Efficacy in Resistant Subgroups: High response rates were maintained irrespective of prior treatment or mutational status. Efficacy was confirmed in patients previously treated with cBTKis and ncBTKis, and in patients with mutations in BTK, MYD88, and CXCR4, the latter being a known mechanism of resistance to ibrutinib.[40]

Efficacy Endpoint	Overall WM Population (N=32-36)	Prior ncBTKi Subgroup (N=3-4)	CXCR4-Mutant Subgroup (N=8)
ORR (Minor Response or better)	84.4% - 90%	100% (3/3 or 4/4)	100% (8/8)
Major Response Rate (PR or better)	75.0% - 81%	N/A	N/A
VGPR Rate	14% - 31.3%	N/A	N/A
Median Time to First Response	~1.0 month	N/A	N/A
Data compiled from CaDAnCe-101 subgroup analyses.40

C. Indolent Non-Hodgkin Lymphoma (iNHL): Follicular (FL) and Marginal Zone (MZL) Lymphoma

BGB-16673 has also shown encouraging clinical activity in other indolent lymphomas, demonstrating the breadth of its potential application.

• Patient Cohort Profile: Patients with FL and MZL were heavily pretreated, with a median of 4.5 and 3.0 prior therapies, respectively.[14] The MZL cohort had a high rate of prior cBTKi exposure (83-86%), consistent with the approval of BTK inhibitors in this disease, whereas the FL cohort had a lower rate of prior BTKi use (12-13%).[13]
• Efficacy Data:
• Follicular Lymphoma (FL): In response-evaluable patients (n=8-12), the ORR was reported to be 42% to 50%, which included a CR rate of 8% (one patient).[13] The median time to first response was approximately 2.6-2.7 months.[13]
• Marginal Zone Lymphoma (MZL): In response-evaluable patients (n=6-20), the ORR was 50% to 67%.[13] Notably, this included a CR rate of 33% (two patients) in one report.[14] The median time to first response was approximately 2.9 months.[13]
• Responses in both histologies were durable, with the majority ongoing at the time of data cutoff, and were observed in patients with prior exposure to both covalent and non-covalent BTK inhibitors.[14]

Efficacy Endpoint	Follicular Lymphoma (N=8-12)	Marginal Zone Lymphoma (N=6-20)
ORR (PR or better)	42% - 50%	50% - 67%
CR Rate	8% (1 patient)	up to 33% (2 patients)
Median Time to First Response	~2.7 months	~2.9 months
Data compiled from CaDAnCe-101 subgroup analyses.13

D. Mantle Cell Lymphoma (MCL)

Data in MCL are more preliminary but indicate that BGB-16673 has clinical activity in this more aggressive lymphoma subtype. An early report from the 2023 ASH Annual Meeting on the first 28 evaluable patients in the study noted that 1 of 3 patients with MCL had responded, achieving a complete response.[19] Expansion cohorts in R/R MCL are actively enrolling, signifying that this is a key area of ongoing investigation for the drug.[4]

V. Consolidated Safety and Tolerability Profile

Across all reported cohorts of the CaDAnCe-101 study, BGB-16673 has demonstrated a consistent, manageable, and generally well-tolerated safety profile. The observed adverse events are largely consistent with on-target inhibition of the BTK pathway and have not revealed unexpected toxicities.[3] A key finding from the dose-escalation portion of the study is that the Maximum Tolerated Dose (MTD) has not been reached at doses up to 600 mg daily, indicating a favorable therapeutic window.[10]

Treatment-Emergent Adverse Events (TEAEs)

• Most Common Any-Grade TEAEs: A predictable pattern of common TEAEs, which are predominantly Grade 1 or 2 in severity, has been observed across the different disease cohorts. The most frequently reported events (in ≥20% of patients in at least one major cohort) include:
• Fatigue: 25% to 37% [2]
• Contusion (bruising): 20% to 32% [2]
• Diarrhea: 23% to 27% [2]
• Neutropenia/Neutrophil count decreased: 16% to 39% [2]
• Upper Respiratory Tract Infection/COVID-19: 15% to 25% [14]
• Most Common Grade ≥3 TEAEs: Severe adverse events are less frequent. Neutropenia is consistently the most common Grade ≥3 TEAE across all studies, with rates ranging from 15% to 31%.[2] This is an expected on-target effect of potent BTK pathway modulation and has been reported as generally manageable with standard supportive care, such as the use of granulocyte colony-stimulating factor (G-CSF).[53] The next most common serious TEAE is pneumonia, occurring at a rate of 10% to 12% in the larger CLL/SLL cohort, which is not unexpected in this heavily pretreated, immunocompromised patient population.[2]

Adverse Events of Special Interest (BTK Class Effects)

A critical aspect of the safety evaluation for any new BTK-targeting agent is the incidence of adverse events known to be associated with the drug class, particularly the cardiovascular toxicities linked to first-generation inhibitors. On this front, BGB-16673 appears to have a highly favorable profile.

• Atrial Fibrillation: The rate of atrial fibrillation is notably low. Early reports from the CaDAnCe-101 study, encompassing dozens of patients, reported no instances of this arrhythmia.[19] In the most mature dataset from the CLL/SLL cohort (N=66), only two cases (3%) were reported; one was a Grade 1 event in a patient with a prior history of atrial fibrillation, and the other was a Grade 2 event that occurred in the context of disease progression and a concurrent infection.[20] In the WM and iNHL cohorts, no cases of atrial fibrillation were observed.[14]
• Hypertension: The incidence of treatment-emergent hypertension is also very low. It was not reported in early analyses.[19] In the iNHL cohort, one patient with a history of hypertension experienced a worsening to Grade 3, which was monitored without specific treatment.[14]
• Major Hemorrhage: Clinically significant bleeding events have been infrequent. In the large CLL/SLL cohort, two patients (3%) experienced major hemorrhage (one Grade 1 subarachnoid hemorrhage and one Grade 3 subdural hemorrhage).[20] One case was reported in the iNHL cohort [14], and no cases were reported in the WM cohort.[40]

The consistently low rates of cardiovascular toxicities, particularly atrial fibrillation and hypertension, represent a potentially significant clinical advantage for BGB-16673. These adverse events are a major concern with the first-generation cBTKi ibrutinib and, while improved with second-generation agents like zanubrutinib, remain a focus of clinical management. The favorable cardiovascular safety profile of BGB-16673 may be attributable to its highly specific mechanism. Off-target kinase inhibition is often implicated in the cardiovascular toxicities of earlier inhibitors. The degradation mechanism, which relies on specific recruitment of BTK to an E3 ligase, may inherently avoid such off-target effects more effectively than even highly selective inhibitors. If this profile is maintained in larger, pivotal trials, it could make BGB-16673 a preferred therapeutic option, especially for the typically older patient population with B-cell malignancies who often have pre-existing cardiovascular comorbidities.

Discontinuations and Fatalities

The rate of treatment discontinuation due to adverse events is low, providing further evidence of the drug's tolerability. In the mature CLL/SLL cohort, only 3% of patients discontinued BGB-16673 due to a treatment-related TEAE.[20] While fatal TEAEs have been reported in the study, none have been attributed to BGB-16673 by the investigators. These events were typically related to infections (e.g., pneumonia, septic shock, aspergillosis) occurring in the context of progressive underlying malignancy in a very frail and heavily pretreated patient population.[10]

Adverse Event	CLL/SLL (N=66)	WM (N=36)	iNHL (FL/MZL) (N=20)
Any-Grade TEAEs
Contusion	30%	31%	20%
Fatigue	37%	N/A	25%
Diarrhea	27%	25%	N/A
Neutropenia	24%	39%	N/A
Grade ≥3 TEAEs
Neutropenia	24%	31%	N/A
Pneumonia	12%	N/A	N/A
Anemia	N/A	17%	N/A
AEs of Special Interest
Atrial Fibrillation (any grade)	3% (2 cases)	0%	5% (1 case, Grade 1)
Hypertension (Grade ≥3)	N/A	0%	5% (1 case, Grade 3)
Major Hemorrhage	3% (2 cases)	0%	5% (1 case)
Data compiled from multiple CaDAnCe-101 presentations.14 N/A indicates not reported as a most common event in that specific cohort's publication.

VI. Strategic Landscape and Future Directions

BGB-16673 is entering a dynamic but well-defined therapeutic landscape for B-cell malignancies. Its unique mechanism of action and compelling early clinical data position it not merely as an additional therapeutic option but as a potentially disruptive agent capable of addressing the primary limitations of the existing BTK inhibitor class.

Competitive Positioning vs. BTK Inhibitors

The strategic value of BGB-16673 is best understood by comparing its profile to the established classes of BTK inhibitors.

• Versus Covalent BTK Inhibitors (cBTKis): BGB-16673 is clearly positioned as a subsequent therapy for the large and growing population of patients whose disease progresses on cBTKis like ibrutinib, acalabrutinib, or BeiGene's own zanubrutinib.[8] The primary mechanism of resistance to cBTKis is the C481S mutation, which BGB-16673 has been shown preclinically and clinically to effectively overcome.[8]
• Versus Non-Covalent BTK Inhibitors (ncBTKis): The most critical competitive dynamic is against the ncBTKi pirtobrutinib, which is the current standard of care for patients who have progressed on a cBTKi. BGB-16673 is being strategically positioned to challenge this standard. The clinical data from CaDAnCe-101 have demonstrated high response rates (ORR of 55% to 71.4%) in patients who have already been treated with and failed an ncBTKi, a population with very few options.[11] This provides proof-of-concept that degradation can overcome ncBTKi resistance. The preclinical data suggesting BGB-16673 is less apt to generate new resistance mutations provides a powerful rationale for potential superiority in terms of response duration.[9] This rationale is the driving force behind the head-to-head Phase 3 trial (NCT06973187), a direct challenge designed to establish BGB-16673 as the preferred agent after cBTKi failure.[21]

Competitive Landscape vs. Other BTK Degraders

BGB-16673 is the most clinically advanced BTK degrader, with over 600 patients treated in its clinical program.[1] However, it is not the only agent in this class. The primary competitor is Nurix Therapeutics' NX-5948, which has also shown promising early data in R/R CLL.[21] A cross-trial comparison presented in one analysis suggested broadly similar efficacy, with BGB-16673 having a slightly higher ORR (72% vs. 67%) but also a potentially higher rate of discontinuation due to adverse events (12% vs. 3%) in early datasets.[42] These comparisons are limited by their cross-trial nature, but they highlight that the race to market for this new class of drugs will be competitive. BGB-16673's current lead in clinical development and the initiation of multiple pivotal trials represent a significant first-mover advantage.

Future Directions and Unanswered Questions

The development program for BGB-16673 points toward several key future directions.

• Combination Therapies: The future of CLL and NHL treatment is moving towards rational, time-limited combination therapies aimed at achieving deep, durable remissions that may allow for treatment discontinuation. The master protocol study (NCT06634589) evaluating BGB-16673 with agents like the BCL2 inhibitor sonrotoclax and CD20xCD3 bispecific antibodies is a critical step in this direction.[33] Combining a BTK degrader with a BCL2 inhibitor, for example, offers the potential for synergistic activity by targeting two distinct and critical survival pathways in B-cell malignancies.
• Movement to Earlier Lines of Therapy: While currently focused on the R/R setting, if BGB-16673 demonstrates superior efficacy and a favorable safety profile (particularly cardiovascular safety) compared to existing BTK inhibitors in its pivotal trials, there is a strong rationale for its investigation in earlier lines of therapy, including as a frontline option for certain high-risk patient populations.[1]
• Central Nervous System (CNS) Activity: A notable preclinical finding was the observation of CNS penetration by BGB-16673.[13] While not yet clinically validated, this property could be a major differentiator, as CNS involvement in lymphoma is a difficult-to-treat condition with a poor prognosis. If confirmed in humans, this could open a significant therapeutic niche for BGB-16673.

Concluding Expert Assessment

BGB-16673 has emerged as a highly promising, first-in-class BTK protein degrader. Its novel mechanism of action—the targeted elimination of the BTK protein—is not merely an incremental advance but a fundamental shift from the paradigm of kinase inhibition. This mechanism has been shown to translate into impressive clinical activity in heavily pretreated and multi-refractory patient populations across a range of B-cell malignancies, most notably CLL/SLL and WM. The drug has demonstrated high and durable response rates in patients who have exhausted all standard therapies, including both covalent and non-covalent BTK inhibitors.

Equally important is its consistently manageable and tolerable safety profile. The observed low rates of cardiovascular adverse events, such as atrial fibrillation and hypertension, represent a significant potential advantage over earlier-generation BTK inhibitors and could be a key factor in physician and patient preference.

BeiGene's aggressive and confident clinical development strategy, highlighted by the initiation of a direct head-to-head Phase 3 trial against pirtobrutinib, signals an intent to position BGB-16673 not just as a salvage therapy but as a potential new standard of care. The outcomes of this trial and other pivotal studies will be critical in defining its ultimate role. In summary, BGB-16673 stands as a leading example of the therapeutic potential of targeted protein degradation and is poised to become a transformative agent in the management of B-cell cancers.

Feature	Covalent BTK Inhibitors (e.g., Ibrutinib, Zanubrutinib)	Non-Covalent BTK Inhibitors (e.g., Pirtobrutinib)	BGB-16673 (BTK Degrader)
Mechanism of Action	Irreversible (covalent) inhibition of BTK kinase activity	Reversible (non-covalent) inhibition of BTK kinase activity	Catalytic degradation of the entire BTK protein via the ubiquitin-proteasome system
Activity vs. C481S Mutation	Inactive (resistance mechanism)	Active	Active
Activity vs. ncBTKi Resistance Mutations (e.g., V416L, T474I)	Active (generally)	Inactive (resistance mechanism)	Active
Propensity to Induce New Resistance (Preclinical)	Can select for C481S mutations	High propensity to select for new kinase domain mutations (100% in one model)	Low propensity to select for on-target BTK mutations (12.7% in one model)
Key Efficacy Signal	High ORR in treatment-naïve and early R/R settings	High ORR in cBTKi-pretreated patients	High ORR in patients pretreated with cBTKi, BCL2i, and ncBTKi (triple-exposed)
Observed Rate of Atrial Fibrillation	Moderate to high (ibrutinib); low (zanubrutinib)	Low	Very low (~3%, with confounders)
Comparative data compiled from the provided research material.9

Works cited

1. BGB-16673 (BTK-targeted Protein Degrader) - BeOne Medicines, accessed September 9, 2025, https://beonemedicines.com/wp-content/uploads/2025/05/Global-BGB-16673-Fact-Sheet.pdf
2. BTK Degrader BGB-16673 Earns FDA Fast Track Status in Pretreated CLL/SLL, accessed September 9, 2025, https://www.cancernetwork.com/view/btk-degrader-bgb-16673-earns-fda-fast-track-status-in-pretreated-cll-sll
3. Results of a Phase I study of BGB-16673, a BTK degrader, for R/R indolent NHL - YouTube, accessed September 9, 2025, https://www.youtube.com/watch?v=YrXrHJV0OEk
4. BGB-16673 - BeOne Medical Affairs | US, accessed September 9, 2025, https://beonemedaffairs.com/us/compound/6858/bgb-16673/
5. BTK Degrader Updates for CLL/SLL - HealthTree for Chronic Lymphocytic Leukemia, accessed September 9, 2025, https://healthtree.org/cll/community/articles/ash-24-btk-degrader-updates-cll-sll
6. BGB-16673, a novel BTK degrader, in patients with R/R B-cell malignancies - YouTube, accessed September 9, 2025, https://www.youtube.com/watch?v=REBMCme8-OY
7. The potential of BGB-16673, a BTK degrader, for the treatment of R/R B-cell malignancies, accessed September 9, 2025, https://www.youtube.com/watch?v=z71GFdA4AfM
8. BGB-16673, A BTK DEGRADER, OVERCOMES ON-TARGET RESISTANCE FROM BTK INHIBITORS AND PRESENTS SUSTAINABLE LONG-TERM TUMOR REGRESSION IN LYMPHOMA XENOGRAFT MODELS - PMC, accessed September 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10431135/
9. P1239: BRUTON TYROSINE KINASE (BTK) PROTEIN DEGRADER ..., accessed September 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10431179/
10. 885 Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study, accessed September 9, 2025, https://ash.confex.com/ash/2024/webprogram/Paper199116.html
11. UPDATED EFFICACY AND SAFETY OF THE BRUTON TYROSINE KINASE (BTK)... - Scarfò L - EHA-3258 - Jun 15 2025, accessed September 9, 2025, https://library.ehaweb.org/eha/2025/eha2025-congress/4159235/lydia.scarf.updated.efficacy.and.safety.of.the.bruton.tyrosine.kinase.28btk29.html?f=
12. First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101) | Blood | American Society of Hematology, accessed September 9, 2025, https://ashpublications.org/blood/article/142/Supplement%201/4401/503732/First-Results-from-a-Phase-1-First-in-Human-Study
13. Updated Efficacy/Safety of Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed/Refractory, accessed September 9, 2025, https://www.beonemedinfo.com/CongressDocuments/Zinzani_BGB-16673-101_ICML_Poster_2025.pdf
14. Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory (R/R) Indolent NHL: Results from the Phase 1 CaDAnCe-101 Study | Blood | American Society of Hematology, accessed September 9, 2025, https://ashpublications.org/blood/article/144/Supplement%201/1649/529309/Preliminary-Efficacy-and-Safety-of-the-Bruton
15. Abstract 410: The BTK degrader BGB-16673 shows anti-tumor activity in marginal zone lymphoma models - AACR Journals, accessed September 9, 2025, https://aacrjournals.org/cancerres/article/85/8_Supplement_1/410/755727/Abstract-410-The-BTK-degrader-BGB-16673-shows-anti
16. BGB-16673 by BeiGene for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval, accessed September 9, 2025, https://www.pharmaceutical-technology.com/data-insights/bgb-16673-beigene-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/
17. www.onclive.com, accessed September 9, 2025, https://www.onclive.com/view/bgb-16673-informs-future-direction-for-btk-degraders-in-relapsed-refractory-cll-sll#:~:text=What%20is%20the%20mechanism%20of,degradation%20via%20the%20proteasome%20pathway.
18. Updated data on the safety and efficacy of BGB-16673 in R/R Waldenström's macroglobulinemia | VJHemOnc, accessed September 9, 2025, https://www.vjhemonc.com/video/tweehzmb8mi-updated-data-on-the-safety-and-efficacy-of-bgb-16673-in-rr-waldenstr%C3%B6ms-macroglobulinemia/?iframe&backpage
19. BGB-16673 Delivers Responses With a Tolerable Safety Profile Across R/R B-Cell Malignancies - OncLive, accessed September 9, 2025, https://www.onclive.com/view/bgb-16673-delivers-reponses-with-a-tolerable-safety-profile-across-r-r-b-cell-malignancies
20. Updated Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory CLL/SLL, accessed September 9, 2025, https://www.beonemedinfo.com/CongressDocuments/Scarfo_BGB-16673-101_RR_CLL_EHA_Presentation_2025.pdf
21. A pivotal push from BeiGene | ApexOnco - Clinical Trials news and analysis, accessed September 9, 2025, https://www.oncologypipeline.com/apexonco/pivotal-push-beigene
22. BeiGene's head-to-head test advances | ApexOnco - Clinical Trials news and analysis, accessed September 9, 2025, https://www.oncologypipeline.com/apexonco/beigenes-head-head-test-advances
23. NCT06973187 | A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | ClinicalTrials.gov, accessed September 9, 2025, https://clinicaltrials.gov/study/NCT06973187
24. A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies | Joint Clinical Trials Office, accessed September 9, 2025, https://jcto.weill.cornell.edu/open_clinical_trials/a-phase-1-open-label-dose-escalation-and-expansion-study-of-the-bruton-tyrosine-kinase-targeted-protein-degrader-bgb-16673-in-patients-with-b-cell-malignancies
25. NCT05006716 | A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies | ClinicalTrials.gov, accessed September 9, 2025, https://www.clinicaltrials.gov/study/NCT05006716
26. A Phase I Study of BGB-16673 in People with B Cell Cancers, accessed September 9, 2025, https://www.mskcc.org/cancer-care/clinical-trials/22-342
27. A Phase 1 Dose-Escalation and Expansion Study of BGB-16673 in Patients With B-Cell Malignancies - BeOne Medicines, accessed September 9, 2025, https://beonemedicines.com/clinical-trials/a-phase-1-dose-escalation-and-expansion-study-of-bgb-16673-in-patients-with-b-cell-malignancies/
28. BGB-16673 Shows Responses With a Manageable Safety Profile Across R/R B-Cell Malignancies, accessed September 9, 2025, https://www.targetedonc.com/view/bgb-16673-shows-responses-with-a-manageable-safety-profile-across-r-r-b-cell-malignancies
29. A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies | Dana-Farber Cancer Institute, accessed September 9, 2025, https://www.dana-farber.org/clinical-trials/23-126
30. A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors - BeOne Medicines, accessed September 9, 2025, https://beonemedicines.com/clinical-trials/a-study-of-bgb-16673-compared-to-investigators-choice-in-participants-with-chronic-lymphocytic-leukemia-previously-exposed-to-both-bruton-tyrosine-kinase-btk-and-b-cell-leukemia-lymphoma-2-protein/
31. A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors | Clinical Research Trial Listing - CenterWatch, accessed September 9, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT06846671/a-study-of-bgb-16673-compared-to-investigators-choice-in-participants-with-chronic-lymphocytic-leukemia-previously-exposed-to-both-bruton-tyrosine-kinase-btk-and-b-cell-leukemia-lymphoma-2-protein-bcl2-inhibitors
32. Dr Scarfò on the Future of BGB-16673 in Relapsed/Refractory CLL/SLL - OncLive, accessed September 9, 2025, https://www.onclive.com/view/dr-scarf-on-the-future-of-bgb-16673-in-relapsed-refractory-cll-sll
33. A phase 1b/2, open-label, master protocol study of BTK-degrader BGB-16673 in combination with other agents in patients with relapsed or refractory B-cell malignancies, accessed September 9, 2025, https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2024-1323.html
34. NCT06634589 | A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies | ClinicalTrials.gov, accessed September 9, 2025, https://clinicaltrials.gov/study/NCT06634589?term=NCT06634589&rank=1
35. NCT06634589 | A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies | ClinicalTrials.gov, accessed September 9, 2025, https://clinicaltrials.gov/study/NCT06634589
36. FDA Fast Tracks BGB-16673 for CLL, SLL - Cure Today, accessed September 9, 2025, https://www.curetoday.com/view/fda-fast-tracks-bgb-16673-for-cll-sll
37. Novel BTK Degrader Earns FDA Fast Track Designation in CLL/SLL - Targeted Oncology, accessed September 9, 2025, https://www.targetedonc.com/view/novel-btk-degrader-earns-fda-fast-track-designation-in-cll-sll
38. FDA Grants Fast Track Designation to BGB-16673 in Previously Treated CLL/SLL - OncLive, accessed September 9, 2025, https://www.onclive.com/view/fda-grants-fast-track-designation-to-bgb-16673-in-previously-treated-cll-sll
39. BeiGene to Present Extensive Hematology Data at EHA 2025, Showcasing BRUKINSA and Next-Generation Therapies - MedPath, accessed September 9, 2025, https://trial.medpath.com/news/87028ce7fc160be1/beigene-to-present-extensive-hematology-data-at-eha-2025-showcasing-brukinsa-and-next-generation-therapies
40. EMA Grants PRIME Designation to BGB-16673 for Previously ..., accessed September 9, 2025, https://www.onclive.com/view/ema-grants-prime-designation-to-bgb-16673-for-previously-treated-waldenstr-m-macroglobulinemia
41. Press Releases - BeOne Medicines NASDAQ, accessed September 9, 2025, https://ir.beonemedicines.com/news-events/press-releases
42. EHA 2024 – Nurix and BeiGene's degraders shine | ApexOnco - Oncology Pipeline, accessed September 9, 2025, https://www.oncologypipeline.com/apexonco/eha-2024-nurix-and-beigenes-degraders-shine
43. BGB-16673 Is Safe, Elicits Nearly 85% ORR in Relapsed/Refractory CLL/SLL - OncLive, accessed September 9, 2025, https://www.onclive.com/view/bgb-16673-is-safe-elicits-nearly-85-orr-in-relapsed-refractory-cll-sll
44. BGB-16673 Informs Future Direction for BTK Degraders in Relapsed/Refractory CLL/SLL, accessed September 9, 2025, https://www.onclive.com/view/bgb-16673-informs-future-direction-for-btk-degraders-in-relapsed-refractory-cll-sll
45. BTK Degrader BGB-16673 Shows Promise in R/R WM and CLL/SLL - Cancer Network, accessed September 9, 2025, https://www.cancernetwork.com/view/btk-degrader-bgb-16673-shows-promise-in-r-r-wm-and-cll-sll
46. Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study | Blood | American Society of Hematology, accessed September 9, 2025, https://ashpublications.org/blood/article/144/Supplement%201/860/530753/Preliminary-Efficacy-and-Safety-of-the-Bruton
47. BGB-16673 Shows Tolerability, Activity in Waldenström Macroglobulinemia, accessed September 9, 2025, https://www.cancernetwork.com/view/bgb-16673-shows-tolerability-activity-in-waldenstr-m-macroglobulinemia
48. Updated data on the safety and efficacy of BGB-16673 in R/R Waldenström's macroglobulinemia - YouTube, accessed September 9, 2025, https://www.youtube.com/watch?v=tWeeHzmB8mI
49. Paper: Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study, accessed September 9, 2025, https://ash.confex.com/ash/2024/webprogram/Paper199212.html
50. Paper: Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase ..., accessed September 9, 2025, https://ash.confex.com/ash/2024/webprogram/Paper199154.html
51. BTK Degrader BGB-16673 Shows Durable Efficacy in Relapsed or Refractory (R/R) Indolent NHL | Blood Cancers Today, accessed September 9, 2025, https://www.bloodcancerstoday.com/post/btk-degrader-bgb-16673-shows-durable-efficacy-in-relapsed-or-refractory-r-r-indolent-nhl
52. Paper: First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101), accessed September 9, 2025, https://ash.confex.com/ash/2023/webprogram/Paper180109.html
53. Dr Scarfò on Early Safety Data With BGB-16673 in R/R CLL/SLL - OncLive, accessed September 9, 2025, https://www.onclive.com/view/dr-scarf-on-early-safety-data-with-bgb-16673-in-r-r-cll-sll